EAGLES
2016
Evaluating Adverse Events in a Global Smoking Cessation Study
In 8,144 smokers with and without psychiatric disorders, varenicline produced higher continuous abstinence at weeks 9–12 than bupropion, nicotine patch or placebo, without excess neuropsychiatric events.
Result
Primary endpoint: Continuous abstinence weeks 9–12; neuropsychiatric adverse events
Abstinence varenicline 33.5%, bupropion 22.6%, NRT 23.4%, placebo 12.5%. No excess NPS adverse events.
- Subtopic
- Varenicline / bupropion / NRT
- Design
- Multicentre 4-arm RCT
- Relevance
- Important: one of several pillars.
- Source
- Anthenelli RM, et al. Lancet. 2016;387(10037):2507-2520.doi 10.1016/S0140-6736(16)30272-0
Discussion & critique
FDA removed the neuropsychiatric black-box warning for varenicline; remains the most effective monotherapy for tobacco dependence.